WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

FRUCTOOLIGOSACCHARIDE (FOS)- A SMART STRATEGY TO MODULATE INFLAMMATORY MARKER AND LIPID PROFILE IN NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) SUBJECTS RESIDING IN ASSAM, INDIA- A RANDOMIZED CONTROL TRIAL.

Mini Sheth*, Abnita Thakuria, Vasundhra Chand and Dr. Mridu Paban Nath

ABSTRACT

Introduction Diabetes mellitus is an important risk factor for CVD. Currently, Fructooligosaccharide (FOS) has been recognized for its potential to improve glycemic, lipemic control and reduce the expression of inflammatory markers. Objective: The study was designed with the broad objective to assess the effect of FOS supplementation to the pre hypertensive type 2 NIDDM subjects in terms of glycemia, lipemia, BMI and hs-CRP levels. Methodology: Using the randomized control trial study design, 35 pre hypertensive adults with type 2 NIDDM aged 35-55yrs were purposively selected from Sun Valley Hospital, Guwahati, Assam, and were randomly divided into Control(N=10) and FOS group (N=25). Background information was collected for glycemia, lipemia, hs-CRP and BMI. The FOS group was supplemented with 10ml of liquid FOS daily to be taken along with meals, for 45 days and post data was collected on the parameters similar to the baseline. Results: FOS supplementation resulted in a significant reduction (p<0.001) in FBS, PP2BS and HbA1c by 6.3%, 9.8% and 10.6% respectively. A significant reduction (p<0.001) was also seen in TG, TC, LDL-C, VLDL by 7.9%, 14.4%, 8%, 9.6% respectively and a significant increase (P<0.001) in HDL-C by 25.1%, while hs-CRP and BMI significantly reduced by 27.2% and 1.3% respectively. Conclusion: Daily intake of 10 ml of liquid FOS can be recommended as an attractive therapy to improve glycemia, lipemia, along with hs-CRP in pre hypertensive type 2 NIDDM subjects.

Keywords: FOS, diabetes mellitus, hypertension, hs-CRP.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More